Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-24, Stock:ABBV, The news for the past five days is as follows:
2018-01-17: NEWS1: AbbVie Named Top Dividend Stock With Insider Buying and 2.77% Yield (ABBV).NEWS2: Is Gilead Sciences, Inc. a Buy in 2018?.NEWS3: Is Gilead Sciences, Inc. a Buy in 2018?.
2018-01-18: NEWS1: Top Research Reports for Apple, JPMorgan & AbbVie.NEWS2: Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?.NEWS3: Can These 4 Large-Cap Drug Stocks Deliver an Encore in &apos;18?.NEWS4: Top Research Reports for Apple, JPMorgan & AbbVie.NEWS5: J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?.NEWS6: A Look into Amgen’s Collaborations in 2H17.NEWS7: J&J (JNJ) Hits New 52-Week High: What&apos;s Driving the Stock?.NEWS8: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS9: How Amgen’s Enbrel and Nplate Are Positioned for 2018.NEWS10: [$$] Buybacks, Pension Contributions and Savings: Companies Tout Tax Benefits.
2018-01-19: NEWS1: How Marijuana Acceptance Is Evolving Globally.NEWS2: Which Biotech Stocks Could Surprise To The Upside On Earnings?.NEWS3: Must-Knows before Investing in the Marijuana Industry.NEWS4: Amgen/Allergan's Avastin Biosimilar Secures EU Approval.NEWS5: Johnson & Johnson’s Pharmaceutical Segment: 4Q17 Estimates.NEWS6: The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group.NEWS7: The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis.NEWS8: Amgen/Allergan&apos;s Avastin Biosimilar Secures EU Approval.NEWS9: The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis.NEWS10: The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group.
2018-01-22: NEWS1: MTUM, BA, ABBV, MCD: Large Inflows Detected at ETF.NEWS2: 3 Top Stocks Bloggers Are Raving Over Right Now.NEWS3: What's in the Cards for Varian Medical (VAR) in Q1 Earnings?.NEWS4: Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?.NEWS5: What's in the Cards for Novartis (NVS) This Earnings Season?.NEWS6: Healthcare ETFs to Watch As Q4 Earnings Unfold.NEWS7: What&apos;s in the Cards for Varian Medical (VAR) in Q1 Earnings?.NEWS8: Is Investment in the Marijuana Space Picking Up?.NEWS9: What&apos;s in the Cards for Novartis (NVS) This Earnings Season?.NEWS10: Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth.NEWS11: The Motivation for Recreational Marijuana Consumption.NEWS12: Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?.NEWS13: Why the Medical Marijuana Industry Is Growing.NEWS14: Merck & Co.’s Cardiovascular and Immunology Products in 3Q17.
2018-01-23: NEWS1: Novartis Announces Positive Results on Migraine Candidate.NEWS2: 3 Large Cap Pharma Stocks to Beat Earnings This Quarter.NEWS3: Vermont Legalizes Recreational Marijuana on January 22, 2018.NEWS4: 3 Large Cap Pharma Stocks to Beat Earnings This Quarter.NEWS5: Stocks Showing Improving Market Leadership: Grifols Earns 82 RS Rating.NEWS6: J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve.NEWS7: The Other Side of Legalizing Recreational Marijuana.NEWS8: J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve.NEWS9: The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck.NEWS10: What a Country Could Gain from Legalizing Recreational Marijuana.NEWS11: The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck.NEWS12: The Marijuana Ecosystem’s Potential Business Opportunities.NEWS13: Analyst Recommendations for Merck & Co. in January 2018.

Answer: Rise